Canada Markets closed

Aequus Pharmaceuticals Inc. (AQS.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.11500.0000 (0.00%)
At close: 3:15PM EDT
Full screen
Previous Close0.1150
Open0.1150
Bid0.1100 x 0
Ask0.1200 x 0
Day's Range0.1150 - 0.1200
52 Week Range0.0900 - 0.2900
Volume147,775
Avg. Volume72,769
Market Cap15.253M
Beta (5Y Monthly)0.42
PE Ratio (TTM)N/A
EPS (TTM)-0.0120
Earnings DateNov. 30, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.52
  • GlobeNewswire

    Aequus Reports Second Quarter 2021 Financial Highlights

    Second Highest Quarterly Revenues in Company HistoryVANCOUVER, British Columbia, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today reported financial results for the quarter ended June 30, 2021 (“Second Quarter 2021”) and associated Company developments. Unless otherwise noted, all figures are in Canadian currenc

  • GlobeNewswire

    Aequus Strengthens Clinical Experience in Stargardt Disease with Pediatric Ophthalmology Expertise

    VANCOUVER, British Columbia, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus”) a speciality pharmaceutical company, is pleased to announce that Dr. Robert K. Koenekoop MD, MSc, PhD, FRCS(C), FARVO has joined as a medical and clinical consultant to Aequus on inherited retinal diseases, and specifically to support Aequus’ collaboration announced July 17, 2021 with reVision Therapeutics, Inc. for the product REV-0100, a potential therapy for Stargar

  • GlobeNewswire

    Aequus and reVision to Collaborate on Stargardt Disease Program

    Aequus Gains Option for North American Commercial RightsVANCOUVER, British Columbia and RIDGEWOOD, N.J., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus”) and reVision Therapeutics, Inc. (“reVision”) announce a collaboration on the development of a therapy for Stargardt disease. Aequus is a specialty pharmaceutical company with multiple commercial eye care products and reVision is a privately-held, biopharmaceutical company focused on the develop